Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22027739 | 0.98 | PNMT (0.47) | PNMTHTR2CHTR2AHTR2BHTR6 | |
| Hydrochloric Acid SCHEMBL16040114 | 0.85 | ADRA2A (0.42) | PNMTHTR2CHTR2AHTR2BHTR6 | |
| SCHEMBL17462466 | 0.83 | PNMT (0.42) | PNMTHTR2CHTR2AHTR2BHTR6 | |
| SCHEMBL2427972 | 0.83 | HTR2C (0.49) | PNMTHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL15502998 | 0.83 | PNMT (0.42) | PNMTHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL19711562 | 0.81 | PNMT (0.41) | PNMTHTR2CHTR2AHTR2BADRA2A | |
| Hydrochloric Acid SCHEMBL31013925 | 0.81 | HTR2C (0.47) | PNMTHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL22858683 | 0.81 | HTR2C (0.51) | PNMTHTR2CHTR2AHTR2B | |
| SCHEMBL19667672 | 0.81 | PNMT (0.47) | PNMTHTR2CHTR2AHTR2BHTR6 | |
| SCHEMBL29608060 | 0.81 | HTR2C (0.51) | PNMTHTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601258-B1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3601258-B1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11046675-B2 | Substituted isoquionline derivatives as immunomudulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200181125-A1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-11 | — | — | US | disclosed |
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-7442710-B2 | Substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1844045-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167023-A1 | Substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181125-A1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | CD74, HLA-DRB1, ICOS | PNMT 118/4885HTR2C 2424/4885HTR2A 3355/4885 |
| US-20060167023-A1 | Substituted phenyl methanones | SLC6A7, SLC1A1, SLC26A3 | PNMT 664/4885HTR2C 506/4885HTR2A 682/4885 |
| US-11046675-B2 | Substituted isoquionline derivatives as immunomudulators | CD74, HLA-DRB1, ICOS | PNMT 118/4885HTR2C 2424/4885HTR2A 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.